Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 7/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.77 |
| ▸ | RAB9A | P51151 | 4/20 | 0.62 |
| ▸ | NPC1 | O15118 | 2/20 | 0.62 |
| ▸ | MAPT | P10636 | 7/20 | 0.60 |
| ▸ | LMNA | P02545 | 4/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | HPGD | P15428 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.59 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12176879 | 0.92 | MEN1 (0.66) | MEN1KMT2ARAB9ANPC1MAPT | |
| SCHEMBL11643697 | 0.92 | MEN1 (0.66) | MEN1KMT2ARAB9ANPC1MAPT | |
| SCHEMBL11642601 | 0.91 | MEN1 (0.64) | MEN1KMT2ARAB9ANPC1MAPT | |
| SCHEMBL11642686 | 0.89 | MEN1 (0.62) | MEN1KMT2ARAB9ANPC1MAPT | |
| SCHEMBL12176915 | 0.89 | MEN1 (0.62) | MEN1KMT2ARAB9ANPC1MAPT | |
| SCHEMBL11648018 | 0.88 | MEN1 (0.60) | MEN1KMT2ARAB9ANPC1MAPT | |
| SCHEMBL21590314 | 0.86 | MEN1 (0.83) | MEN1KMT2ARAB9ANPC1MAPT | |
| SCHEMBL8661871 | 0.85 | MEN1 (0.82) | MEN1KMT2ARAB9ANPC1MAPT | |
| SCHEMBL7141724 | 0.85 | TSHR (0.72) | MEN1KMT2ARAB9ANPC1MAPT | |
| SCHEMBL7755042 | 0.84 | MEN1 (0.54) | MEN1KMT2ARAB9ANPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012022707-A1 | SUBSTITUTED HETEROARYL SPIROPYRROLIDINE MDM2 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-02-23 | — | — | WO | disclosed |
| US-20120046306-A1 | Substituted Heteroaryl Spiropyrrolidine MDM2 Antagonists | BARTKOVITZ DAVID JOSEPH (US) | 2012-02-23 | — | — | US | disclosed |
| EP-1603572-A4 | LACTAM-CONTAINING CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2008-06-25 | — | — | EP | disclosed |
| US-20070135428-A1 | LACTAM CONTAINING CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS | QIAO JENNIFER X | 2007-06-14 | — | — | US | disclosed |
| US-7205318-B2 | Lactam-containing cyclic diamines and derivatives as a factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-04-17 | — | — | US | disclosed |
| EP-1603572-A1 | LACTAM-CONTAINING CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS | Bristol-Myers Squibb Company (US) | 2005-12-14 | — | — | EP | disclosed |
| US-20040204454-A1 | Lactam-containing cyclic diamines and derivatives as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-10-14 | — | — | US | disclosed |
| WO-2004082687-A1 | LACTAM-CONTAINING CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-09-30 | — | — | WO | disclosed |
| US-4816452-A | ANTIBIOTICS | BEECHAM GROUP P.L.C. (GB) | 1989-03-28 | — | — | US | disclosed |
| EP-0210815-A2 | 6-Beta-(alpha-etherified oxyimino)-acylamino penicillanic-acid derivatives, their preparation and use | BEECHAM GROUP PLC (GB) | 1987-02-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135428-A1 | LACTAM CONTAINING CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS | F12, F2, PEPD | MEN1 228/4885KMT2A 1997/4885RAB9A 3566/4885 |
| US-20040204454-A1 | Lactam-containing cyclic diamines and derivatives as factor Xa inhibitors | PEPD, TFPI, F2 | MEN1 505/4885KMT2A 1633/4885RAB9A 2636/4885 |
| US-20120046306-A1 | Substituted Heteroaryl Spiropyrrolidine MDM2 Antagonists | MDM2, TP53, RB1 | MEN1 1998/4885KMT2A 1667/4885RAB9A 2171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.